A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03490-6
Abstract: Imatinib, a small-molecule tyrosine kinase inhibitor, has shown good clinical activity by inhibiting adenosine triphosphate (ATP) binding to the receptor. Unfortunately, majority of patients eventually develop drug resistance, which limits the long-term benefits of the… read more here.
Keywords: inhibits kit; kit; kit dimer; dimerisation ... See more keywords